Alex Harding is a  Senior Vice President of Business Development and Corporate Strategy at Remix Therapeutics, a Boston-based biotech company developing small molecules that alter RNA processing prior to protein translation. Their REMaster platform “enables the design of molecules that can selectively degrade RNA, enhance RNA expression, induce exon skipping or rescue genetic lesions.” Their technology “can address undrugged disease drivers across therapeutic areas to rapidly bring new medicines to patients.”Alex came to Remix from VC firm Atlas Venture, where he served as a Senior Associate and Entrepreneur-in-Residence following the completion of his Medical Residency at Massachusetts General Hospital. In addition to his full-time role at Remix, Alex continues to practice medicine and serves foundations dedicated to the advancement of healthcare.Alex is a Baltimore native, and Hopkins alum- having received his MD from JHU-SOM and an MBA from Harvard Business School.Hosted by Jenna Glatzer and Gustavo Carrizo.